A randomized study to evaluate tolerance, pharmacokinetics, and short term efficacy of seven doses of the short –acting formulation of ICI 182,780 in women prior to surgery for primary breast cancer.
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
No locations available